80 related articles for article (PubMed ID: 12512697)
1. Synthesis and thrombolytic activity of new thienopyrimidinone derivatives.
Dupin JP; Gryglewski RJ; Gravier D; Hou G; Casadebaig F; Swies J; Chlopicki S
J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):625-34. PubMed ID: 12512697
[TBL] [Abstract][Full Text] [Related]
2. Thrombolysis by thienopyridines and their congeners.
Gryglewski RJ; Dupin JP; Uracz W; Swiês J; Madej J; Hou G; Gravier D; Casadebaig F
J Physiol Pharmacol; 2000 Dec; 51(4 Pt 1):683-93. PubMed ID: 11192941
[TBL] [Abstract][Full Text] [Related]
3. Effect of ticlopidine on streptokinase-induced thrombolysis in rats.
Gryglewski RJ; Korbut R; Swies J; Uracz W
Wien Klin Wochenschr; 1999 Feb; 111(3):98-102. PubMed ID: 10093891
[TBL] [Abstract][Full Text] [Related]
4. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
[TBL] [Abstract][Full Text] [Related]
5. Effects of clopidogrel and ticlopidine on experimental diabetic ischemic retinopathy in rats.
De La Cruz P; Arrebola M; González-Correa A; Martinez-Cerdán E; Moreno A; de la Cuesta FS
Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):204-10. PubMed ID: 12595963
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
7. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD
Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334
[TBL] [Abstract][Full Text] [Related]
8. Kinins and thrombolysis.
Swies J; Chłopicki S; Gryglewski RJ
J Physiol Pharmacol; 1993 Jun; 44(2):171-7. PubMed ID: 8358053
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the antithrombotic effects of heparin, hirudin and clopidogrel according to the nature of the thrombogenic surface in an arterioarterial shunt in rats.
Léger P; Magues JP; Freund M; Cazenave JP; Boneu B
Thromb Haemost; 1999 Sep; 82(3):1203-4. PubMed ID: 10494794
[No Abstract] [Full Text] [Related]
10. Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart.
Jakubowski A; Chlopicki S; Olszanecki R; Jawien J; Lomnicka M; Dupin JP; Gryglewski RJ
Prostaglandins Leukot Essent Fatty Acids; 2005 Feb; 72(2):139-45. PubMed ID: 15626597
[TBL] [Abstract][Full Text] [Related]
11. Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor.
Vilahur G; Pena E; Padró T; Badimon L
Thromb Haemost; 2007 Apr; 97(4):650-7. PubMed ID: 17393029
[TBL] [Abstract][Full Text] [Related]
12. Effects of clopidogrel on survival of rat skin flaps.
Ersoy A; Sevin K; Sevin A; Serel S
J Plast Reconstr Aesthet Surg; 2007; 60(8):861-3. PubMed ID: 17418655
[TBL] [Abstract][Full Text] [Related]
13. Vane's blood-bathed organ technique adapted to examine the endothelial effects of cardiovascular drugs in vivo.
Gryglewski RJ; Mackiewicz Z
Pharmacol Rep; 2010; 62(3):462-7. PubMed ID: 20631409
[TBL] [Abstract][Full Text] [Related]
14. Thrombolytic action of ticlopidine: possible mechanisms.
Gryglewski RJ; Korbut R; Swies J; Kostka Trabka E; Bieroń K; Robak J
Eur J Pharmacol; 1996 Jul; 308(1):61-7. PubMed ID: 8836633
[TBL] [Abstract][Full Text] [Related]
15. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of new class dipeptide analogues with improved permeability and antithrombotic activity.
Zhao M; Bi L; Bi W; Wang C; Yang Z; Ju J; Peng S
Bioorg Med Chem; 2006 Jul; 14(14):4761-74. PubMed ID: 16616499
[TBL] [Abstract][Full Text] [Related]
17. Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel.
Lorrain J; Lechaire I; Gauffeny C; Masson R; Roome N; Herault JP; O'Connor SE; Schaeffer P; Herbert JM
J Pharmacol Exp Ther; 2004 Apr; 309(1):235-40. PubMed ID: 14718579
[TBL] [Abstract][Full Text] [Related]
18. ADP receptors: inhibitory strategies for antiplatelet therapy.
Cattaneo M
Drug News Perspect; 2006 Jun; 19(5):253-9. PubMed ID: 16941047
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
[TBL] [Abstract][Full Text] [Related]
20. ADP receptors: inhibitory strategies for antiplatelet therapy.
Cattaneo M
Timely Top Med Cardiovasc Dis; 2006 Sep; 10():E22. PubMed ID: 17066149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
